Immix Biopharma (IMMX)
(Delayed Data from NSDQ)
$2.19 USD
+0.10 (4.78%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.24 +0.05 (2.28%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMMX 2.19 +0.10(4.78%)
Will IMMX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IMMX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMMX
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?
IMMX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IMMX
IMMX Crossed Above 20 Day Moving Average on September 20
Directional Movement Crossover Bullish appears for IMMX after 6.63% move
IMMX forms Stochastic Reached Oversold on September 17
Is IMMX signaling selling opportunity? MACD Bearish Signal Line Cross shows up after slipping 4.31%
Insider Buying: Ilya Rachman Acquires Additional Shares of Immix Biopharma Inc (IMMX)